Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Rogier van der Velde

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
EJIFCC|September 30, 2016
ST2 and Galectin-3: Ready for Prime Time?Wouter C Meijers, A Rogier van der Velde, Rudolf A de Boer
Current Heart Failure Reports|June 24, 2014
Biomarkers for risk prediction in acute decompensated heart failureA Rogier van der Velde, Wouter C Meijers, Rudolf A de Boer
Expert Review of Molecular Diagnostics|March 11, 2014
The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failureWouter C Meijers, A Rogier van der Velde, Rudolf A de Boer
Clinica Chimica Acta; International Journal of Clinical Chemistry|December 3, 2014
Galectin-3 and heart failure: prognosis, prediction & clinical utilityMando D Filipe, Wouter C Meijers, A Rogier van der Velde, et al.
European Journal of Pharmacology|June 24, 2015
Galectin-3 and post-myocardial infarction cardiac remodelingWouter C Meijers, A Rogier van der Velde, Domingo A Pascual-Figal, et al.
European Journal of Heart Failure|October 22, 2016
Variability of biomarkers in patients with chronic heart failure and healthy controlsWouter C Meijers, A Rogier van der Velde, Anneke C Muller Kobold, et al.
Circulation. Heart Failure|February 12, 2013
Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACHA Rogier van der Velde, Lars Gullestad, Thor Ueland, et al.
Cardiovascular Drugs and Therapy|May 3, 2014
Galectin-3: a modifiable risk factor in heart failureRudolf A de Boer, A Rogier van der Velde, Christian Mueller, et al.
International Journal of Cardiology|August 10, 2016
Determinants of temporal changes in galectin-3 level in the general population: Data of PREVENDA Rogier van der Velde, Wouter C Meijers, Edwin R van den Heuvel, et al.
American Journal of Physiology. Renal Physiology|December 16, 2014
Pharmacological inhibition of galectin-3 protects against hypertensive nephropathyAnne-Roos S Frenay, Lili Yu, A Rogier van der Velde, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
EJIFCC|September 30, 2016
ST2 and Galectin-3: Ready for Prime Time?Wouter C Meijers, A Rogier van der Velde, Rudolf A de Boer
Current Heart Failure Reports|June 24, 2014
Biomarkers for risk prediction in acute decompensated heart failureA Rogier van der Velde, Wouter C Meijers, Rudolf A de Boer
Expert Review of Molecular Diagnostics|March 11, 2014
The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failureWouter C Meijers, A Rogier van der Velde, Rudolf A de Boer
Clinica Chimica Acta; International Journal of Clinical Chemistry|December 3, 2014
Galectin-3 and heart failure: prognosis, prediction & clinical utilityMando D Filipe, Wouter C Meijers, A Rogier van der Velde, et al.
European Journal of Pharmacology|June 24, 2015
Galectin-3 and post-myocardial infarction cardiac remodelingWouter C Meijers, A Rogier van der Velde, Domingo A Pascual-Figal, et al.
European Journal of Heart Failure|October 22, 2016
Variability of biomarkers in patients with chronic heart failure and healthy controlsWouter C Meijers, A Rogier van der Velde, Anneke C Muller Kobold, et al.
Circulation. Heart Failure|February 12, 2013
Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACHA Rogier van der Velde, Lars Gullestad, Thor Ueland, et al.
Cardiovascular Drugs and Therapy|May 3, 2014
Galectin-3: a modifiable risk factor in heart failureRudolf A de Boer, A Rogier van der Velde, Christian Mueller, et al.
International Journal of Cardiology|August 10, 2016
Determinants of temporal changes in galectin-3 level in the general population: Data of PREVENDA Rogier van der Velde, Wouter C Meijers, Edwin R van den Heuvel, et al.
American Journal of Physiology. Renal Physiology|December 16, 2014
Pharmacological inhibition of galectin-3 protects against hypertensive nephropathyAnne-Roos S Frenay, Lili Yu, A Rogier van der Velde, et al.
Pageof 2